For the past several years, PorzioLS has published an annual White Paper analyzing the evolution of the global transparency movement. A primary catalyst for the rapid acceleration of the transparency movement was the adoption by the European Federation of Pharmaceutical Industries and Associations ("EFPIA"), which is comprised of thirty-three national member associations and forty pharmaceutical companies, of the "EFPIA Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations" ("Disclosure Code").
The transparency movement goes well beyond EFPIA, however, as there have been legislative reporting developments recently in France, Denmark, Portugal, Romania, Greece, England, and Scotland. Geographically, the global transparency movement extends to the Pacific Rim, as the Japanese and Australian pharmaceutical industry groups modified their individual-level reporting requirements in 2015.
There were also many developments over the past year in the United States, the birthplace of the transparency movement. Transparency of HCP interactions is affecting not only innovative pharmaceutical companies but other parts of the life sciences industry as well.
To read the full white paper, click here.